Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective
ObjectiveTo evaluate the cost-utility of different dosing regimens of PCSK9 inhibitors, added to statin therapy, in patients with hypercholesterolemia or at high cardiovascular risk in China.MethodsA Markov cohort multistate-transition model was developed from the perspective of the Chinese healthca...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2025-11-01
|
| Col·lecció: | Frontiers in Pharmacology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1708701/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|